Neuronal derivative mediators that regulate cutaneous inflammations

Critical Reviews in Immunology

Volumn 32, Issue 4, 2012, Pages 307-320

  Mikami, Norihisa ^a   Fukada, So ichiro ^a   Yamamoto, Hiroshi ^b   Tsujikawa, Kazutake ^a  

^a OSAKA UNIVERSITY   (Japan)

^b KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

GPCRs; Neuropeptide; Skin inflammation

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN RECEPTOR LIKE RECEPTOR; CALCIUM CHANNEL; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; G PROTEIN COUPLED RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; NEUROKININ 3 RECEPTOR; NEUROKININ B; NEUROPEPTIDE Y; NEUROTRANSMITTER; PHOSPHOLIPASE C; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; SUBSTANCE P; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; ATOPIC DERMATITIS; BINDING AFFINITY; CONTACT ALLERGY; CYTOKINE PRODUCTION; DERMATITIS; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOREGULATION; NERVE ENDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RECEPTOR BINDING; REGULATORY MECHANISM; SENSORY NERVE; SIGNAL TRANSDUCTION; SKIN ALLERGY; TH1 CELL; TH2 CELL;

EID: 84871281225     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevImmunol.v32.i4.20     Document Type: Article

References (124)

1. Kimber I, Dearman RJ. Allergic contact dermatitis: the cellular effectors. Contact Dermatitis. 2002;46:1-5.
2. Hayashi M, Higashi K, Kato H, Kaneko H. Assessment of preferential Th1 or Th2 induction by low-molecular-weight compounds using a reverse transcription-polymerase chain reaction method: comparison of two mouse strains, C57BL/6 and BALB/c. Toxicol Appl Pharmacol. 2001;177:38-45.
3. Hopkins JE, Naisbitt DJ, Kitteringham NR, Dearman RJ, Kimber I, Park BK. Selective haptenation of cellular or extracellular protein by chemical allergens: association with cytokine polarization. Chem Res Toxicol. 2005;18:375-81.
4. van Beelen AJ, Teunissen MB, Kapsenberg ML, de Jong EC. Interleukin-17 in inflammatory skin disorders. Curr Opin Allergy Clin Immunol. 2007;7:374-81.
5. Bhalla AK. Hormones and the immune response. Ann Rheum Dis. 1989;48:1-6.
6. Franco R, Pacheco R, Lluis C, Ahern GP, O'Connell PJ. The emergence of neurotransmitters as immune modulators. Trends Immunol. 2007;28:400-7.
7. Steinhoff M, Stander S, Seeliger S, Ansel JC, Schmelz M, Luger T. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol. 2003;139:1479-88.
8. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998;393:333-9.
9. Van Valen F, Piechot G, Jurgens H. Calcitonin gene-related peptide (CGRP) receptors are linked to cyclic adenosine monophosphate production in SK-N-MC human neuroblastoma cells. Neurosci Lett. 1990;119:195-8.
10. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature. 1985;313:54-6.
11. Liu J, Chen M, Wang X. Calcitonin gene-related peptide inhibits lipopolysaccharide-induced interleukin-12 release from mouse peritoneal macrophages, mediated by the cAMP pathway. Immunology. 2000;101:61-7.
12. Tsujikawa K, Yayama K, Hayashi T, Matsushita H, Yamaguchi T, Shigeno T, Ogitani Y, Hirayama M, Kato T, Fukada S, Takatori S, Kawasaki H, Okamoto H, Ikawa M, Okabe M, Yamamoto H. Hypertension and dysregulated proinflammatory cytokine production in receptor activitymodifying protein 1-deficient mice. Proc Natl Acad Sci U S A. 2007;104:16702-7.
13. Boudard F, Bastide M. Inhibition of mouse T-cell proliferation by CGRP and VIP: effects of these neuropeptides on IL-2 production and cAMP synthesis. J Neurosci Res. 1991;29:29-41.
14. Tokoyoda K, Tsujikawa K, Matsushita H, Ono Y, Hayashi T, Harada Y, Abe R, Kubo M, Yamamoto H. Up-regulation of IL-4 production by the activated cAMP/cAMP-dependent protein kinase (protein kinase A) pathway in CD3/ CD28-stimulated naive T cells. Int Immunol. 2004;16:643-53.
15. Mikami N, Watanabe K, Hashimoto N, Fukada S, Yamamoto H, Tsujikawa K. Calcitonin gene-related peptide enhances experimental autoimmune encephalomyelitis by promoting Th17 cell functions. Int Immunol. Int Immunol. 2012;24:681-91.
16. Dalsgaard CJ, Jernbeck J, Stains W, Kjartansson J, Haegerstrand A, Hokfelt T, Brodin E, Cuello AC, Brown JC. Calcitonin gene-related peptide-like immunoreactivity in nerve fibers in the human skin. Relation to fibers containing substance P-, somatostatin-and vasocactive intestinalpolypeptide-like immunoreactivity. Histochemistry. 1989;91:35-8.
17. Hosoi J, Murphy GF, Egan CL, Lerner EA, Grabbe S, Asahina A, Granstein RD. Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. Nature. 1993;363:159-63.
18. Asahina A, Moro O, Hosoi J, Lerner EA, Xu S, Takashima A, Granstein RD. Specific induction of cAMP in Langerhans cells by calcitonin generelated peptide: relevance to functional effects. Proc Natl Acad Sci U S A. 1995;92:8323-7.
19. Ding W, Wagner JA, Granstein RD. CGRP, PACAP, and VIP modulate Langerhans cell function by inhibiting NF-kappaB activation. J Invest Dermatol. 2007;127:2357-67.
20. Ding W, Stohl LL, Wagner JA, Granstein RD. Calcitonin gene-related peptide biases Langerhans cells toward Th2-type immunity. J Immunol. 2008;181:6020-6.
21. Girolomoni G, Tigelaar RE. Capsaicin-sensitive primary sensory neurons are potent modulators of murine delayed-type hypersensitivity reactions. J Immunol. 1990;145:1105-12.
22. Gutwald J, Goebeler M, Sorg C. Neuropeptides enhance irritant and allergic contact dermatitis. J Invest Dermatol. 1991;96:695-8.
23. Maruyama T, Iizuka H, Tobisawa Y, Shiba T, Matsuda T, Kurohane K, Imai Y. Influence of local treatments with capsaicin or allyl isothiocyanate in the sensitization phase of a fluoresceinisothiocyanate-induced contact sensitivity model. Int Arch Allergy Immunol. 2007;143:144-54.
24. Asahina A, Hosoi J, Beissert S, Stratigos A, Granstein RD. Inhibition of the induction of delayed-type and contact hypersensitivity by calcitonin gene-related peptide. J Immunol. 1995;154:3056-61.
25. Niizeki H, Alard P, Streilein JW. Calcitonin gene-related peptide is necessary for ultraviolet B-impaired induction of contact hypersensitivity. J Immunol. 1997;159:5183-6.
26. Mikami N, Matsushita H, Kato T, Kawasaki R, Sawazaki T, Kishimoto T, Ogitani Y, Watanabe K, Miyagi Y, Sueda K, Fukada S, Yamamoto H and Tsujikawa K. Calcitonin gene-related peptide is an important regulator of cutaneous immunity: effect on dendritic cell and T cell functions. J Immunol. 2011;186:6886-93.
27. Ostlere LS, Cowen T, Rustin MH. Neuropeptides in the skin of patients with atopic dermatitis. Clin Exp Dermatol. 1995;20:462-7.
28. Hodeib A, El-Samad ZA, Hanafy H, El-Latief AA, El-Bendary A, Abu-Raya A. Nerve growth factor, neuropeptides and cutaneous nerves in atopic dermatitis. Indian J Dermatol. 2010;55:135-9.
29. Antunez C, Torres MJ, Lopez S, Rodriguez-Pena R, Blanca M, Mayorga C, Santamaria-Babi LF. Calcitonin gene-related peptide modulates interleukin-13 in circulating cutaneous lymphocyte-associated antigen-positive T cells in patients with atopic dermatitis. Br J Dermatol. 2009;161:547-53.
30. Jarvikallio A, Harvima IT, Naukkarinen A. Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch Dermatol Res. 2003;295:2-7.
31. De Jonge F, De Laet A, Van Nassauw L, Brown JK, Miller HR, van Bogaert PP, Timmermans JP, Kroese AB. In vitro activation of murine DRG neurons by CGRP-mediated mucosal mast cell degranulation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G178-G191.
32. Regoli D, Nguyen K, Calo G. Neurokinin receptors. Comparison of data from classical pharmacology, binding, and molecular biology. Ann N Y Acad Sci. 1997;812:144-6.
33. Helke CJ, Krause JE, Mantyh PW, Couture R, Bannon MJ. Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms. FASEB J. 1990;4:1606-15.
34. Ohkubo H, Nakanishi S. Molecular characterization of the three tachykinin receptors. Ann N Y Acad Sci. 1991;632:53-62.
35. Holst B, Hastrup H, Raffetseder U, Martini L, Schwartz TW. Two active molecular phenotypes of the tachykinin NK1 receptor revealed by G-protein fusions and mutagenesis. J Biol Chem. 2001;276:19793-9.
36. Palanche T, Ilien B, Zoffmann S, Reck MP, Bucher B, Edelstein SJ, Galzi JL. The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J Biol Chem. 2001;276:34853-61.
37. Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science. 1988;241:1218-21.
38. Laurenzi MA, Persson MA, Dalsgaard CJ, Haegerstrand A. The neuropeptide substance P stimulates production of interleukin 1 in human blood monocytes: activated cells are preferentially influenced by the neuropeptide. Scand J Immunol. 1990;31:529-33.
39. Kincy-Cain T, Bost KL. Substance P-induced IL-12 production by murine macrophages. J Immunol. 1997;158:2334-9.
40. Scholzen TE, Steinhoff M, Sindrilaru A, Schwarz A, Bunnett NW, Luger TA, Armstrong CA, Ansel JC. Cutaneous allergic contact dermatitis responses are diminished in mice deficient in neurokinin 1 receptors and augmented by neurokinin 2 receptor blockage. FASEB J. 2004;18:1007-9.
41. Lambrecht BN, Germonpre PR, Everaert EG, Carro-Muino I, De Veerman M, de Felipe C, Hunt SP, Thielemans K, Joos GF, Pauwels RA. Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation. Eur J Immunol. 1999;29:3815-25.
42. Wagner F, Fink R, Hart R, Dancygier H. Substance P enhances interferon-gamma production by human peripheral blood mononuclear cells. Regul Pept. 1987;19:355-64.
43. Calvo CF, Chavanel G and Senik A. Substance P enhances IL-2 expression in activated human T cells. J Immunol. 1992;148:3498-504.
44. Cunin P, Caillon A, Corvaisier M, Garo E, Scotet M, Blanchard S, Delneste Y, Jeannin P. The tachykinins substance P and hemokinin-1 favor the generation of human memory Th17 cells by inducing IL-1beta, IL-23, and TNFlike 1A expression by monocytes. J Immunol. 2011;186:4175-82.
45. Barros PO, Ferreira TB, Vieira MM, Almeida CR, Araujo-Lima CF, Silva-Filho RG, Hygino J, Andrade RM, Andrade AF, Bento CA. Substance P enhances Th17 phenotype in individuals with generalized anxiety disorder: an event resistant to glucocorticoid inhibition. J Clin Immunol. 2011;31:51-9.
46. Niizeki H, Kurimoto I, Streilein JW. A substance p agonist acts as an adjuvant to promote hapten-specific skin immunity. J Invest Dermatol. 1999;112:437-42.
47. Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol. 2002;147:71-9.
48. Pincelli C, Fantini F, Massimi P, Girolomoni G, Seidenari S, Giannetti A. Neuropeptides in skin from patients with atopic dermatitis: an immunohistochemical study. Br J Dermatol. 1990;122:745-50.
49. Kang H, Byun DG, Kim JW. Effects of substance P and vasoactive intestinal peptide on interferongamma and interleukin-4 production in severe atopic dermatitis. Ann Allergy Asthma Immunol. 2000;85:227-32.
50. Gordon DJ, Ostlere LS, Holden CA. Neuropeptide modulation of Th1 and Th2 cytokines in peripheral blood mononuclear leucocytes in atopic dermatitis and non-atopic controls. Br J Dermatol. 1997;137:921-7.
51. Grip L, Lonne-Rahm SB, Holst M, Johansson B, Nordlind K, Theodorsson E, El-Nour H. Substance P alterations in skin and brain of chronically stressed atopic-like mice. J Eur Acad Dermatol Venereol. 2012. Jan. 18. 2012;doi: 10.1111/j.1468-308.
52. Katsuno M, Aihara M, Kojima M, Osuna H, Hosoi J, Nakamura M, Toyoda M, Matsuda H, Ikezawa Z. Neuropeptides concentrations in the skin of a murine (NC/Nga mice) model of atopic dermatitis. J Dermatol Sci. 2003;33:55-65.
53. Ohmura T, Tsunenari I, Hayashi T, Satoh Y, Konomi A, Nanri H, Kawachi M, Morikawa M, Kadota T, Satoh H. Role of substance P in an NC/Nga mouse model of atopic dermatitis-like disease. Int Arch Allergy Immunol. 2004;133:389-97.
54. Lin S, Boey D, Herzog H. NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides. 2004;38:189-200.
55. Bedoui S, Kawamura N, Straub RH, Pabst R, Yamamura T, von Horsten S. Relevance of neuropeptide Y for the neuroimmune crosstalk. J Neuroimmunol. 2003;134:1-11.
56. Kawamura N, Tamura H, Obana S, Wenner M, Ishikawa T, Nakata A, Yamamoto H. Differential effects of neuropeptides on cytokine production by mouse helper T cell subsets. Neuroimmunomodulation. 1998;5:9-15.
57. Bedoui S, Miyake S, Lin Y, Miyamoto K, Oki S, Kawamura N, Beck-Sickinger A, von Horsten S, Yamamura T. Neuropeptide Y (NPY) suppresses experimental autoimmune encephalomyelitis: NPY1 receptor-specific inhibition of autoreactive Th1 responses in vivo. J Immunol. 2003;171:3451-8.
58. Wheway J, Mackay CR, Newton RA, Sainsbury A, Boey D, Herzog H, Mackay F. A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. J Exp Med. 2005;202: 1527-38.
59. Stadler J, Le TP, Haas P, Nave H. Distinct effects of NPY13-36, a specific NPY Y2 agonist, in a model of rodent endotoxemia on leukocyte subsets and cytokine levels. Ann Anat. 2011;193:486-93.
60. Macia L, Rao PT, Wheway J, Sierro F, Mackay F, Herzog H. Y1 signalling has a critical role in allergic airway inflammation. Immunol Cell Biol. 2011;89:882-8.
61. Tobin D, Nabarro G, Baart de la Faille H, van Vloten WA, van der Putte SC, Schuurman HJ. Increased number of immunoreactive nerve fibers in atopic dermatitis. J Allergy Clin Immunol. 1992;90:613-22.
62. Salomon J, Baran E. The role of selected neuropeptides in pathogenesis of atopic dermatitis. J Eur Acad Dermatol Venereol. 2008;22:223-8.
63. Wallengren J. Vasoactive peptides in the skin. J Investig Dermatol Symp Proc. 1997;2:49-55.
64. Waeber B, Burnier M, Nussberger J, Brunner HR. Role of atrial natriuretic peptides and neuropeptide Y in blood pressure regulation. Horm Res. 1990;34:161-5.
65. Laburthe M, Couvineau A. Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP. Regul Pept. 2002;108:165-73.
66. Laburthe M, Couvineau A, Marie JC. VPAC receptors for VIP and PACAP. Receptors Channels. 2002;8:137-53.
67. Villalba M, Bockaert J, Journot L. Pituitary adenylate cyclase-activating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway. J Neurosci. 1997;17:83-90.
68. McCulloch DA, MacKenzie CJ, Johnson MS, Robertson DN, Holland PJ, Ronaldson E, Lutz EM, Mitchell R. Additional signals from VPAC/ PAC family receptors. Biochem Soc Trans. 2002;30:441-6.
69. Barrie AP, Clohessy AM, Buensuceso CS, Rogers MV, Allen JM. Pituitary adenylyl cyclase-activating peptide stimulates extracellular signal-regulated kinase 1 or 2 (ERK1/2) activity in a Ras-independent, mitogen-activated protein Kinase/ERK kinase 1 or 2-dependent manner in PC12 cells. J Biol Chem. 1997;272: 19666-71.
70. Tang H, Sun L, Xin Z, Ganea D. Down-regulation of cytokine expression in murine lymphocytes by PACAP and VIP. Ann N Y Acad Sci. 1996;805:768-78.
71. Jiang X, Wang HY, Yu J, Ganea D. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes. Ann N Y Acad Sci. 1998;865:397-407.
72. Delgado M, Leceta J, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J Immunol. 1999;163:3629-35.
73. Delgado M, Leceta J, Sun W, Gomariz RP, Ganea D. VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression. Ann N Y Acad Sci. 2000;921:68-78.
74. Delgado M, Leceta J, Abad C, Martinez C, Ganea D, Gomariz RP. Shedding of membranebound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. J Neuroimmunol. 1999;99:61-71.
75. Chorny A, Gonzalez-Rey E, Varela N, Robledo G, Delgado M. Signaling mechanisms of vasoactive intestinal peptide in inflammatory conditions. Regul Pept. 2006;137:67-74.
76. Pozo D, Gonzalez-Rey E, Chorny A, Anderson P, Varela N, Delgado M. Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders. Peptides. 2007;28:1833-46.
77. Kodali S, Ding W, Huang J, Seiffert K, Wagner JA, Granstein RD. Vasoactive intestinal peptide modulates Langerhans cell immune function. J Immunol. 2004;173:6082-8.
78. Kodali S, Friedman I, Ding W, Seiffert K, Wagner JA, Granstein RD. Pituitary adenylate cyclase-activating polypeptide inhibits cutaneous immune function. Eur J Immunol. 2003;33:3070-9.
79. Ding W, Manni M, Stohl LL, Zhou XK, Wagner JA, Granstein RD. Pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation toward Th17 cells. Eur J Immunol. 2012;42:901-11.
80. Yadav M, Rosenbaum J, Goetzl EJ. Cutting edge: vasoactive intestinal peptide (VIP) induces differentiation of Th17 cells with a distinctive cytokine profile. J Immunol. 2008;180:2772-6.
81. Yadav M, Goetzl EJ. Vasoactive intestinal peptidemediated Th17 differentiation: an expanding spectrum of vasoactive intestinal peptide effects in immunity and autoimmunity. Ann NY Acad Sci. 2008;1144:83-9.
82. Kemeny A, Reglodi D, Cseharovszky R, Hashimoto H, Baba A, Szolcsanyi J, Pinter E, Helyes Z. Pituitary adenylate cyclase-activating polypeptide deficiency enhances oxazoloneinduced allergic contact dermatitis in mice. J Mol Neurosci. 2010;42:443-9.
83. Lundeberg L, Mutt V, Nordlind K. Inhibitory effect of vasoactive intestinal peptide on the challenge phase of allergic contact dermatitis in humans. Acta Derm Venereol. 1999;79:178-82.
84. Bondesson L, Nordlind K, Mutt V, Liden S. Vasoactive intestinal polypeptide inhibits the established allergic contact dermatitis in humans. Ann N Y Acad Sci. 1996;805:702-7.
85. Lundeberg L, Nordlind K. Vasoactive intestinal polypeptide in allergic contact dermatitis: an immunohistochemical and radioimmunoassay study. Arch Dermatol Res. 1999;291:201-6.
86. Umemoto N, Kakurai M, Okazaki H, Kiyosawa T, Demitsu T, Nakagawa H. Serum levels of vasoactive intestinal peptide are elevated in patients with atopic dermatitis. J Dermatol Sci. 2003;31:161-4.
87. Lonne-Rahm S, Berg M, Marin P, Nordlind K. Atopic dermatitis, stinging, and effects of chronic stress: a pathocausal study. J Am Acad Dermatol. 2004;51:899-905.
88. Tsuboi K, Sugimoto Y, Ichikawa A. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat. 2002;68-69:535-56.
89. Boswell MG, Zhou W, Newcomb DC, Peebles RS Jr. PGI2 as a regulator of CD4+ subset differentiation and function. Prostaglandins Other Lipid Mediat. 2011;96:21-6.
90. Sakata D, Yao C, Narumiya S. Emerging roles of prostanoids in T cell-mediated immunity. IUBMB Life. 2010;62:591-6.
91. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004;103:147-66.
92. Boniface K, Bak-Jensen KS, Li Y, Blumenschein WM, McGeachy MJ, McClanahan TK, McKenzie BS, Kastelein RA, Cua DJ, de Waal Malefyt R. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. 2009;206:535-48.
93. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, Sugimoto Y, Narumiya S. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med. 2009;15:633-40.
94. Esaki Y, Li Y, Sakata D, Yao C, Segi-Nishida E, Matsuoka T, Fukuda K, Narumiya S. Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2010;107:12233-8.
95. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest. 2001;108:15-23.
96. Chiba T, Ueki S, Ito W, Kato H, Kamada R, Takeda M, Kayaba H, Furue M, Chihara J. The opposing role of two prostaglandin D2 receptors, DP and CRTH2, in human eosinophil migration. Ann Allergy Asthma Immunol. 2011;106:511-7.
97. Xue L, Gyles SL, Wettey FR, Gazi L, Townsend E, Hunter MG, Pettipher R. Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol. 2005;175:6531-6.
98. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, Ichimasa M, Sugamura K, Nakamura M, Takano S, Nagata K. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seventransmembrane receptor CRTH2. J Exp Med. 2001;193:255-61.
99. Kabashima K, Sakata D, Nagamachi M, Miyachi Y, Inaba K, Narumiya S. Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med. 2003;9:744-9.
100. Nagamachi M, Sakata D, Kabashima K, Furuyashiki T, Murata T, Segi-Nishida E, Soontrapa K, Matsuoka T, Miyachi Y, Narumiya S. Facilitation of Th1-mediated immune response by prostaglandin E receptor EP1. J Exp Med. 2007;204:2865-74.
101. Honda T, Matsuoka T, Ueta M, Kabashima K, Miyachi Y, Narumiya S. Prostaglandin E(2)-EP(3) signaling suppresses skin inflammation in murine contact hypersensitivity. J Allergy Clin Immunol. 2009;124:809-18.e2.
102. Rheins LA, Barnes L, Amornsiripanitch S, Collins CE, Nordlund JJ. Suppression of the cutaneous immune response following topical application of the prostaglandin PGE2. Cell Immunol. 1987;106:33-42.
103. Yamamoto Y, Otani S, Hirai H, Nagata K, Aritake K, Urade Y, Narumiya S, Yokozeki H, Nakamura M, Satoh T. Dual functions of prostaglandin D2 in murine contact hypersensitivity via DP and CRTH2. Am J Pathol. 2011;179:302-14.
104. Matsushima Y, Satoh T, Yamamoto Y, Nakamura M, Yokozeki H. Distinct roles of prostaglandin D2 receptors in chronic skin inflammation. Mol Immunol. 2011;49:304-10.
105. He R, Oyoshi MK, Wang JY, Hodge MR, Jin H, Geha RS. The prostaglandin D receptor CRTH2 is important for allergic skin inflammation after epicutaneous antigen challenge. J Allergy Clin Immunol. 2010;126:784-90.
106. Satoh T, Moroi R, Aritake K, Urade Y, Kanai Y, Sumi K, Yokozeki H, Hirai H, Nagata K, Hara T, Utsuyama M, Hirokawa K, Sugamura K, Nishioka K, Nakamura M. Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J Immunol. 2006;177:2621-9.
107. Boehme SA, Franz-Bacon K, Chen EP, Sasik R, Sprague LJ, Ly TW, Hardiman G, Bacon KB. A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation. Int Immunol. 2009;21:81-93.
108. Kanda N, Koike S, Watanabe S. Prostaglandin E2 enhances neurotrophin-4 production via EP3 receptor in human keratinocytes. J Pharmacol Exp Ther. 2005;315:796-804.
109. Iwasaki M, Nagata K, Takano S, Takahashi K, Ishii N, Ikezawa Z. Association of a new-type prostaglandin D2 receptor CRTH2 with circulating T helper 2 cells in patients with atopic dermatitis. J Invest Dermatol. 2002;119:609-16.
110. Yahara H, Satoh T, Miyagishi C, Yokozeki H. Increased expression of CRTH2 on eosinophils in allergic skin diseases. J Eur Acad Dermatol Venereol. 2010;24:75-6.
111. Eigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G, Endres S. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol. 1998;63:101-7.
112. Blomhoff HK, Smeland EB, Beiske K, Blomhoff R, Ruud E, Bjoro T, Pfeifer-Ohlsson S, Watt R, Funderud S, Godal T, Ohlsson R. Cyclic AMPmediated suppression of normal and neoplastic B cell proliferation is associated with regulation of myc and Ha-ras protooncogenes. J Cell Physiol. 1987;131:426-33.
113. Kaneko T, Alvarez R, Ueki IF, Nadel JA. Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils. Cell Signal. 1995;7:527-34.
114. Aronoff DM, Canetti C, Peters-Golden M. Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptormediated increase in intracellular cyclic AMP. J Immunol. 2004;173:559-65.
115. Heo JY, Cho YS, Cheon HG. Topical effects of roflumilast on 1-chloro-2,4-dinitrobenzeneinduced atopic dermatitis-like skin lesions in NC/Nga mice. Pharmazie. 2010;65:906-12.
116. Kaminuma O, Mori A, Suko M, Nishizaki Y, Kikkawa H, Ikezawa K, Okudaira H. A novel phosphodiesterase inhibitor, T-440: possible management of eosinophilic inflammation by down-regulation of interleukin-5 production. Int Arch Allergy Immunol. 111. Suppl. 1996;1:16-8.
117. Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson WR Jr, Kirby DS, Weiner ES. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol. 1996;107:51-6.
118. Rundfeldt C, Steckel H, Sorensen T, Wlaz P. The stable cyclic adenosine monophosphate analogue, dibutyryl cyclo-adenosine monophosphate (bucladesine), is active in a model of acute skin inflammation. Arch Dermatol Res. 2012. Feb. 2012;3.
119. Marshall AJ, Niiro H, Yun TJ, Clark EA. Regulation of B-cell activation and differentiation by the phosphatidylinositol 3-kinase and phospholipase Cgamma pathway. Immunol Rev. 2000;176:30-46.
120. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27:591-619.
121. Hu L, Edamatsu H, Takenaka N, Ikuta S, Kataoka T. Crucial role of phospholipase Cepsilon in induction of local skin inflammatory reactions in the elicitation stage of allergic contact hypersensitivity. J Immunol. 2010;184:993-1002.
122. Ikuta S, Edamatsu H, Li M, Hu L, Kataoka T. Crucial role of phospholipase C epsilon in skin inflammation induced by tumor-promoting phorbol ester. Cancer Res. 2008;68:64-72.
123. Oka M, Edamatsu H, Kunisada M, Hu L, Takenaka N, Sakaguchi M, Kataoka T, Nishigori C. Phospholipase Cvarepsilon has a crucial role in ultraviolet B-induced neutrophil-associated skin inflammation by regulating the expression of CXCL1/KC. Lab Invest. 2011;91:711-8.
124. Mallett RB, Myint S, Holden CA. Measurement of phosphoinositide-specific phospholipase C activity in mononuclear leucocytes from atopic and normal subjects. Br J Dermatol. 1992;127:97-102.